Search

Displaying results 2901 - 2910 of 7498 in total
  1. Drug

    Pascopyrum smithii pollen

    go.drugbank.com/drugs/DB10719
    Approved

    Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  2. Drug

    Resveratrol

    go.drugbank.com/drugs/DB02709
    Investigational

    Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. … The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr.

    Mixtures: Co-Balamin, Co-Veratrol
  3. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. … The FDA issued a warning letter regarding this risk to health care professionals and patients.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Other advantages of HSC transplantation include a lower risk of transmitting infections by latent viruses and improved targeting of ethnic minorities increased pool of rare haplotypes [A32219]. … Upon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function [

  5. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115].

  6. Drug

    Travoprost

    go.drugbank.com/drugs/DB00287
    ApprovedInvestigational

    It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension.

  7. Drug

    Tocopherol

    go.drugbank.com/drugs/DB11251
    ApprovedInvestigational

    When the carbons at position 5- and 7- are not methylated, they can function as electrophilic centers that can trap reactive oxygen and nitrogen species. … The classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring.

  8. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  9. Drug

    Pipecuronium

    go.drugbank.com/drugs/DB01338
    ApprovedInvestigationalWithdrawn

    Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

  10. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. … Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is